TABLE 2.

Treatment-Emergent Nonhematologic Grade ≥3 AEs Occurring in >1 Patient in All Cycles (Safety Population)

MedDRA-Preferred Term Total	Schedule 1, <1.25 mg/m2 FIL or BTZ = 1.0 N = 26	Schedule 1, ≥1.25 mg/m2 FIL and BTZ = 1.3 N = 19	Schedule 2 N = 10	Total Treated N = 55
Total no. of patients with any grade ≥3 AE (%)	18 (69)	12 (63)	7 (70)	37 (67)
Lipase increased	0 (0)	4 (21)	2 (20)	6 (11)
Blood amylase increased	1 (4)	2 (11)	1 (10)	4 (7)
Pneumonia	3 (12)	0 (0)	1 (10)	4 (7)
Cholecystitis	1 (4)	0 (0)	1 (10)	2 (4)
Fall	1 (4)	0 (0)	1 (10)	2 (4)
Hyperuricemia	2 (8)	0 (0)	0 (0)	2 (4)
Hyponatremia	2 (8)	0 (0)	0 (0)	2 (4)

Abbreviations: AE, adverse event; BTZ, bortezomib; FIL, filanesib; MedDRA, Medical Dictionary for Regulatory Activities (version 13.0).